Showing 181-190 of 333 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Stem Cell-derived Islet Vascularized Extracellular Matrix Organoids for Enhanced Transplantation Success | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Jon Odorico | Cures | 01-January-2024 to 31-December-2026 | $1.394.960,67 |
| A prodrug system for targeted activation of small molecules in beta cells | The Brigham and Women’s Hospital, Inc. | Amit Choudhary | Cures | 01-February-2024 to 31-January-2027 | $2.250.000,00 |
| Sparing ER stressed human beta cells with novel kinase inhibitors of the unfolded protein response (UPR) | The Regents of the University of California, San Francisco | Feroz Papa | Cures | 01-August-2023 to 31-July-2026 | $960.000,00 |
| Validation of a new approach for cardiovascular disease risk stratification and therapeutic targeting in T1D | Joslin Diabetes Center Inc. | Myra Lipes | Improving Lives | 01-September-2023 to 31-December-2025 | $966.378,00 |
| Hybrid Closed Loop Therapy for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study (CLVerEX) | Regents of the University of Minnesota | Antoinette Moran | Cures | 01-April-2023 to 31-March-2026 | $1.739.442,00 |
| Repurposing LRRK2 inhibitors for β cell protection in T1D | Regents of the University of Michigan | Scott Soleimanpour | Cures | 01-September-2023 to 31-August-2026 | $750.000,00 |
| Risk and Protective Factors for Optimal Health Outcomes in Children with Type 1 Diabetes (T1D) and their Parents | Ann & Robert H. Lurie Children’s Hospital of Chicago | Jillian Merrick | Transportfolio | 01-September-2023 to 31-August-2025 | $129.046,51 |
| Adult T1D Detection at Geisinger | IQVIA, Inc. | Nadejda Leavitt | Cures | 01-July-2023 to 31-December-2025 | $890.727,00 |
| Targeting the Opposing Roles of Prostaglandin E2 Receptors, EP3 and EP4, in the Pathogenesis of Type One Diabetes | Vanderbilt University Medical Center (VUMC) | Maureen Gannon | Cures | 01-October-2023 to 30-September-2025 | $200.000,00 |
| Oxygen Enabled High-capacity Vascularized Devices for ß-cell Replacement Therapy in Humans | Arizona Board of Regents, University of Arizona | Klearchos Papas | Cures | 01-September-2023 to 31-August-2026 | $2.652.490,70 |